Top > Find a Doctor > Narikazu Boku

Narikazu Boku

Narikazu Boku
Departments/Divisions

Cancer Center

Titles

M.D., Ph.D.

Expertise/Specialties

Chemotherapy for Gastrointestinal Malignant disease, Supportive Care for Cancer Treatment

Research Interests

New drug development, Clinical trial, Translational Research

Languages

Japanese/ English

Education
Year Institution Degree
1987 The University of Tokyo Medical School M.D.
2008 University of Tsukuba Ph.D.
Training
Years attended Institution Discipline
1987 The University of Tokyo Hospital Internship
1988 The Central Hospital of Social Health Insurance Internship
1989 The National Cancer Center Hospital Trainee
Appointments and positions
Years Institution Title
1992 National Cancer Center Hospital East Staff physician, Division of Digestive Endoscopy and Gastrointestinal Oncology
2002 Shizuoka Cancer Center Hospital Chief, Division of Gastrointestinal Oncology
2010 St. Marianna University School of Medicine Professor, Department of Clinical Oncology
2015 National Cancer Center Hospital Chief, Division of Gastrointestinal Medical Oncology
2021 IMSUT Hospital, Insitute of Medical Science, University of Tokyo Professor, Department of Oncology and General Medicine
Selected Publications
  • Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin. Cancer Res. 1998
  • Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: randomised phase 3 study. Lancet Oncology.
  • Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016
  • Kang YK, Boku N, Satoh T, Ryu NH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang, WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017
Academic Societies
  • American Society of Clinical Oncology
  • European Society of Medical Oncology
  • Japanese Society of Medical Oncology
  • Japanese Cancer Association
  • Japan Society of Clinical Oncology
  • Japanese Gastric Cancer Association
  • Japanese Gastric Cancer Association
  • Japanese Association of Supportive Care in Cancer
  • Japanese Society of Gastroenterology
Editorial Boards
  • Associate Editor, Gastric Cancer
  • Associate Editor, Japanese Journal of Clinical Oncology
  • Associate Editor, Esophagus

page top